MS-Tailored Weight Loss Program Achieves Meaningful Results MS-Tailored Weight Loss Program Achieves Meaningful Results
People with multiple sclerosis and obesity can achieve substantial weight loss, leading to improved mobility and quality of life, with a specially designed program, new trial results suggest.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 16, 2023 Category: Endocrinology Tags: Neurology & Neurosurgery News Source Type: news
Path to Multiple Sclerosis Cure on the Horizon
(MedPage Today) -- MILAN -- A path to a cure for multiple sclerosis (MS) may be on the horizon, a top MS researcher suggested.
The field faces a great opportunity to advance from suppressing the disease to curing it, said Stephen Hauser, MD... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 16, 2023 Category: Neurology Source Type: news
Subcutaneous Ocrelizumab Not Inferior to IV Infusion
(MedPage Today) -- MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III OCARINA II trial showed... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 14, 2023 Category: Neurology Source Type: news
Late-breaking data for Roche ’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS)More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at 8 weeksThe safety profile of fenebrutinib was consistent with previous and ongoing clinical trials across more than 2,500 people to dateBasel, 13 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from the Phase II FENopta study showing that inve...
Source: Roche Media News - October 13, 2023 Category: Pharmaceuticals Source Type: news
Late-breaking data for Roche ’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS)More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at 8 weeksThe safety profile of fenebrutinib was consistent with previous and ongoing clinical trials across more than 2,500 people to dateBasel, 13 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from the Phase II FENopta study showing that inve...
Source: Roche Investor Update - October 13, 2023 Category: Pharmaceuticals Source Type: news
Novel Drug Shows Promise in Multiple Sclerosis
(MedPage Today) -- MILAN -- Treatment with investigational frexalimab, a novel CD40 ligand (CD40L) inhibitor, led to sustained reduction of MRI disease activity in relapsing multiple sclerosis (MS) at 6 months, follow-up data from a phase II... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 13, 2023 Category: Neurology Source Type: news
Ocrelizumab Benefit Confirmed in Older Patients With MS Ocrelizumab Benefit Confirmed in Older Patients With MS
The relapse benefit of ocrelizumab in multiple sclerosis is confirmed for the first time in patients 60 and older starting therapy, say researchers in findings they hope will inform choices.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 13, 2023 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
AI Tool Reveals MS Drug Interactions, Offers Safer Options AI Tool Reveals MS Drug Interactions, Offers Safer Options
Clinicians prescribing a drug for patients with multiple sclerosis who are on multiple treatments may in future use AI to identify potential interactions and suggest safer options, new data suggest.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 12, 2023 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
New data for Roche ’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided
10-year efficacy data highlight OCREVUS ’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from over 6,000 patients continue to reinforce consistent long-term safety profile of OCREVUSMore than 3,200 women with MS treated with OCREVUS reported no increased risk in adverse pregnancy and infant outcomes with real-world analyses showing low risk of relapse during and after pregnancyOCREVUS controlled disease activity and progression over one year in Black and Hispanic / Latinx people with MSBasel, 12 October 2023 - Roch...
Source: Roche Media News - October 12, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided
10-year efficacy data highlight OCREVUS ’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from over 6,000 patients continue to reinforce consistent long-term safety profile of OCREVUSMore than 3,200 women with MS treated with OCREVUS reported no increased risk in adverse pregnancy and infant outcomes with real-world analyses showing low risk of relapse during and after pregnancyOCREVUS controlled disease activity and progression over one year in Black and Hispanic / Latinx people with MSBasel, 12 October 2023 - Roch...
Source: Roche Investor Update - October 12, 2023 Category: Pharmaceuticals Source Type: news
Subjective and objective cognition in patients driving with multiple sclerosis - Schecter R, Foley F.
OBJECTIVE: Multiple sclerosis (MS) is a disease of the central nervous system that results in focal lesions of demyelination, inflammation, and axonal damage to the brain and spinal cord. MS affects nearly one million people in the United States. Drivers w... (Source: SafetyLit)
Source: SafetyLit - October 11, 2023 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
Using virtual reality driving simulation to determine cognitive correlates of turning behaviors among drivers with and without multiple sclerosis - Dheer S, Ang J, Devlin K, Schultheis M.
This study uses a virtual reality driving simulator (VRDS) to 1) compare turning behavior between adults with or without MS; 2) identify cognitive correlates of turning behavior. METHOD: 64 community-dwelling adult drivers, including 38 ... (Source: SafetyLit)
Source: SafetyLit - October 11, 2023 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
Roche ’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeksOCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeksThe safety profile of OCREVUS subcutaneous injection was consistent with the well-established safety profile of OCREVUS IV infusionThe 10-minute subcutaneous injection has potential to improve the treatment experience and expand usage for people with multiple sclerosis (MS) in centres...
Source: Roche Media News - October 11, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeksOCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeksThe safety profile of OCREVUS subcutaneous injection was consistent with the well-established safety profile of OCREVUS IV infusionThe 10-minute subcutaneous injection has potential to improve the treatment experience and expand usage for people with multiple sclerosis (MS) in centres...
Source: Roche Investor Update - October 11, 2023 Category: Pharmaceuticals Source Type: news
Risky movement: assessing fall risk in people with multiple sclerosis with wearable sensors and beacon-based smart-home monitoring - Kushner T, Mosquera-Lopez C, Hildebrand A, Cameron MH, Jacobs PG.
BACKGROUND: People with multiple sclerosis (PwMS) fall frequently causing injury, social isolation, and decreased quality of life. Identifying locations and behaviors associated with high fall risk could help direct fall prevention interventions. Here we d... (Source: SafetyLit)
Source: SafetyLit - October 9, 2023 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news
